Key result
Alternate-day aspirin shows marked primary prevention benefit, prompting early trial termination for efficacy.
RCT
Double-blind
Randomized
Answers are grounded in this paper and cite their sources.
The Physicians' Health Study is a randomized, double-blind, placebo-controlled trial testing two primary-prevention hypotheses: (1) whether 325 mg of aspirin (as Bufferin, supplied by Bristol-Myers Products) taken every other day reduces mortality from cardiovascular disease, and (2) whether 50 mg of beta carotene (as Lurotin, supplied by BASF) taken on alternate days decreases the incidence of cancer.1 At a special meeting on December 18, 1987, the external Data Monitoring Board of the Physicians' Health Study took the unusual step of recommending the early termination of the randomized aspirin component of the trial, primarily because a statistically extreme beneficial effect on . . .
No takes yet. Share an insight, caveat, or question.
A 1988 study conducted an RCT in Cardiovascular disease and cancer primary prevention. Aspirin (Bufferin) vs. Placebo was evaluated on Mortality from cardiovascular disease. Aspirin 325 mg taken every other day demonstrated a statistically extreme beneficial effect in primary prevention, prompting early termination of the trial's aspirin component.
Synapse has enriched 10 related papers. Consider them for comparative context: